-
1
-
-
33745392178
-
Late sodium current in the pathophysiology of cardiovascular disease: Consequences of sodium-calcium overload
-
Noble D, Noble PJ. Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload. Heart 2006; 92: 41-45.
-
(2006)
Heart
, vol.92
, pp. 41-45
-
-
Noble, D.1
Noble, P.J.2
-
2
-
-
84891675409
-
Efficacy and safety of ranolazine in patients with chronic stable angina
-
Kloner RA, Hines ME, Geunes-Boyer S. Efficacy and safety of ranolazine in patients with chronic stable angina. Postgrad Med 2014; 125: 43-52.
-
(2014)
Postgrad Med
, vol.125
, pp. 43-52
-
-
Kloner, R.A.1
Hines, M.E.2
Geunes-Boyer, S.3
-
3
-
-
70449090162
-
Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion
-
Dhalla AK, Wang WQ, Dow J, Shryock JC, Belardinelli L, Bhandari A. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2009; 297: H1923-1929.
-
(2009)
Am J Physiol Heart Circ Physiol
, vol.297
, pp. H1923-H1929
-
-
Dhalla, A.K.1
Wang, W.Q.2
Dow, J.3
Shryock, J.C.4
Belardinelli, L.5
Bhandari, A.6
-
4
-
-
84895195235
-
The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials
-
Banon D, Filion KB, Budlovsky T, Franck C, Eisenberg MJ. The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials. Am J Cardiol 2014; 113: 1075-1082.
-
(2014)
Am J Cardiol
, vol.113
, pp. 1075-1082
-
-
Banon, D.1
Filion, K.B.2
Budlovsky, T.3
Franck, C.4
Eisenberg, M.J.5
-
5
-
-
84930716398
-
Ranolazine treatment for myocardial infarction? Effects on the development of necrosis, left ventricular function and arrhythmias in experimental models
-
Hale SL, Kloner RA. Ranolazine treatment for myocardial infarction? Effects on the development of necrosis, left ventricular function and arrhythmias in experimental models. Cardiovasc Drugs Ther 2014; 28: 469-475.
-
(2014)
Cardiovasc Drugs Ther
, vol.28
, pp. 469-475
-
-
Hale, S.L.1
Kloner, R.A.2
-
6
-
-
84928107038
-
The beneficial effects of ranolazine on cardiac function after myocardial infarction are greater in diabetic than in nondiabetic rats
-
Mourouzis I, Mantzouratou P, Galanopoulos G, Kostakou E, Dhalla AK, Belardinelli L, Pantos C. The beneficial effects of ranolazine on cardiac function after myocardial infarction are greater in diabetic than in nondiabetic rats. J Cardiovasc Pharmacol Ther 2014; 19: 457-469.
-
(2014)
J Cardiovasc Pharmacol Ther
, vol.19
, pp. 457-469
-
-
Mourouzis, I.1
Mantzouratou, P.2
Galanopoulos, G.3
Kostakou, E.4
Dhalla, A.K.5
Belardinelli, L.6
Pantos, C.7
-
7
-
-
84944321678
-
Eplerenone attenuates cardiac dysfunction and oxidative stress in betareceptor stimulated myocardial infarcted rats
-
Reddy NM, Mahajan UB, Patil CR, Agrawal YO, Ojha S, Goyal SN. Eplerenone attenuates cardiac dysfunction and oxidative stress in betareceptor stimulated myocardial infarcted rats. Am J Transl Res 2015; 7: 1602-1611.
-
(2015)
Am J Transl Res
, vol.7
, pp. 1602-1611
-
-
Reddy, N.M.1
Mahajan, U.B.2
Patil, C.R.3
Agrawal, Y.O.4
Ojha, S.5
Goyal, S.N.6
-
8
-
-
84940763035
-
Aldosterone contributes to sympathoexcitation in renovascular hypertension
-
Lincevicius GS, Shimoura CG, Nishi EE, Perry JC, Casarini DE, Gomes GN, Bergamaschi CT, Campos RR. Aldosterone contributes to sympathoexcitation in renovascular hypertension. Am J Hypertens 2015; 28: 1083-1090.
-
(2015)
Am J Hypertens
, vol.28
, pp. 1083-1090
-
-
Lincevicius, G.S.1
Shimoura, C.G.2
Nishi, E.E.3
Perry, J.C.4
Casarini, D.E.5
Gomes, G.N.6
Bergamaschi, C.T.7
Campos, R.R.8
-
9
-
-
0021194420
-
Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
-
Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-823.
-
(1984)
N Engl J Med
, vol.311
, pp. 819-823
-
-
Cohn, J.N.1
Levine, T.B.2
Olivari, M.T.3
Garberg, V.4
Lura, D.5
Francis, G.S.6
Simon, A.B.7
Rector, T.8
-
10
-
-
17444440057
-
Autonomic response to coronary occlusion in animals susceptible to ventricular fibrillation
-
Collins MN, Billman GE. Autonomic response to coronary occlusion in animals susceptible to ventricular fibrillation. Am J Physiol 1989; 257: H1886-1894.
-
(1989)
Am J Physiol
, vol.257
, pp. H1886-H1894
-
-
Collins, M.N.1
Billman, G.E.2
-
11
-
-
0025653393
-
Sympathetic--parasympathetic interaction and sudden death
-
Vanoli E, Schwartz PJ. Sympathetic--parasympathetic interaction and sudden death. Basic Res Cardiol 1990; 85: 305-321.
-
(1990)
Basic Res Cardiol
, vol.85
, pp. 305-321
-
-
Vanoli, E.1
Schwartz, P.J.2
-
12
-
-
31944447449
-
Sympathetic nervous system neuroplasticity
-
Esler M, Kaye D. Sympathetic nervous system neuroplasticity. Hypertension 2006; 47: 143-144.
-
(2006)
Hypertension
, vol.47
, pp. 143-144
-
-
Esler, M.1
Kaye, D.2
-
13
-
-
0035199136
-
Progression of heart failure after myocardial infarction in the rat
-
Francis J, Weiss RM, Wei SG, Johnson AK, Felder RB. Progression of heart failure after myocardial infarction in the rat. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1734-1745.
-
(2001)
Am J Physiol Regul Integr Comp Physiol
, vol.281
, pp. R1734-R1745
-
-
Francis, J.1
Weiss, R.M.2
Wei, S.G.3
Johnson, A.K.4
Felder, R.B.5
-
14
-
-
33847066216
-
Plasma brain natriuretic peptide correlates with infarct size but not with subsequent remodeling in the rat heart
-
Maczewski M, Mackiewicz U. Plasma brain natriuretic peptide correlates with infarct size but not with subsequent remodeling in the rat heart. Cardiovasc Pathol 2007; 16: 79-84.
-
(2007)
Cardiovasc Pathol
, vol.16
, pp. 79-84
-
-
Maczewski, M.1
Mackiewicz, U.2
-
15
-
-
33750513635
-
Brain natriuretic peptide and other risk markers for outcome assess ment in patients with non-ST-elevation coronary syndromes and preserved systolic function
-
Palazzuoli A, Deckers J, Calabro A, Campagna MS, Nuti R, Pastorelli M, Pasgui AL, Bruni F, Auteri A, Puccetti L. Brain natriuretic peptide and other risk markers for outcome assess ment in patients with non-ST-elevation coronary syndromes and preserved systolic function. Am J Cardiol 2006; 98: 1322-1328.
-
(2006)
Am J Cardiol
, vol.98
, pp. 1322-1328
-
-
Palazzuoli, A.1
Deckers, J.2
Calabro, A.3
Campagna, M.S.4
Nuti, R.5
Pastorelli, M.6
Pasgui, A.L.7
Bruni, F.8
Auteri, A.9
Puccetti, L.10
-
16
-
-
0037432301
-
Val-HeFT Investigators. Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT)
-
Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN; Val-HeFT Investigators. Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107: 1278-1283.
-
(2003)
Circulation
, vol.107
, pp. 1278-1283
-
-
Anand, I.S.1
Fisher, L.D.2
Chiang, Y.T.3
Latini, R.4
Masson, S.5
Maggioni, A.P.6
Glazer, R.D.7
Tognoni, G.8
Cohn, J.N.9
-
17
-
-
73449094578
-
Prognostic Value of Emerging Neurohormones in Chronic Heart Failure during Optimization of Heart Failure-Specific Therapy
-
Neuhold S, Huelsmann M, Strunk G, Struck J, Adlbrecht C, Gouya G. Prognostic Value of Emerging Neurohormones in Chronic Heart Failure during Optimization of Heart Failure-Specific Therapy. Clin Chem 2010; 56: 121-126.
-
(2010)
Clin Chem
, vol.56
, pp. 121-126
-
-
Neuhold, S.1
Huelsmann, M.2
Strunk, G.3
Struck, J.4
Adlbrecht, C.5
Gouya, G.6
-
18
-
-
33646140572
-
Clinical Pharmacokinetics of Ranolazine
-
Jerling M. Clinical Pharmacokinetics of Ranolazine. Clin Pharmacokinet 2006; 45: 469-491.
-
(2006)
Clin Pharmacokinet
, vol.45
, pp. 469-491
-
-
Jerling, M.1
-
19
-
-
18344393246
-
Posttranscriptional Control of BNP Gene Expression in Angiotensin II-Induced Hypertension
-
Suo M, Hautala N, Földes G, Szokodi I, Tóth M, Leskinen H. Posttranscriptional Control of BNP Gene Expression in Angiotensin II-Induced Hypertension. Hypertension 2002; 39: 803-808.
-
(2002)
Hypertension
, vol.39
, pp. 803-808
-
-
Suo, M.1
Hautala, N.2
Földes, G.3
Szokodi, I.4
Tóth, M.5
Leskinen, H.6
-
20
-
-
0022591615
-
Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure
-
Leimbach WN, Wallin BG, Victor RG, Aylward PE, Sundlöf G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986; 73: 913-919.
-
(1986)
Circulation
, vol.73
, pp. 913-919
-
-
Leimbach, W.N.1
Wallin, B.G.2
Victor, R.G.3
Aylward, P.E.4
Sundlöf, G.5
Mark, A.L.6
-
21
-
-
0034700994
-
Exaggerated Renal Vasoconstriction During Exercise in Heart Failure Patients
-
Middlekauff HR, Nitzsche EU, Hoh CK, Hamilton MA, Fonarow GC, Hage A, Moriguchi JD. Exaggerated Renal Vasoconstriction During Exercise in Heart Failure Patients. Circulation 2000; 101: 784-789.
-
(2000)
Circulation
, vol.101
, pp. 784-789
-
-
Middlekauff, H.R.1
Nitzsche, E.U.2
Hoh, C.K.3
Hamilton, M.A.4
Fonarow, G.C.5
Hage, A.6
Moriguchi, J.D.7
-
22
-
-
0025287313
-
Sympathetic activity and regional blood flow in heart failure
-
Dargie H. Sympathetic activity and regional blood flow in heart failure. Eur Heart J 1990; 11: 39-43.
-
(1990)
Eur Heart J
, vol.11
, pp. 39-43
-
-
Dargie, H.1
-
23
-
-
84887491765
-
Effects of ranolazine in symptomatic patients with stable coronary artery disease
-
Savarese G, Rosano G, D’Amore C, Musella F, Della Ratta GL, Pellegrino AM, Formisano T, Vitagliano A, Cirillo A, Cice G, Fimiani L, del Guercio L, Trimarco B, Perrone-Filardi P. Effects of ranolazine in symptomatic patients with stable coronary artery disease. Int J Cardiol 2013; 169: 262-270.
-
(2013)
Int J Cardiol
, vol.169
, pp. 262-270
-
-
Savarese, G.1
Rosano, G.2
D’Amore, C.3
Musella, F.4
Della Ratta, G.L.5
Pellegrino, A.M.6
Formisano, T.7
Vitagliano, A.8
Cirillo, A.9
Cice, G.10
Fimiani, L.11
Del Guercio, L.12
Trimarco, B.13
Perrone-Filardi, P.14
-
24
-
-
0027524995
-
Factors contributing to the exercise limitation of heart failure
-
Wilson JR, Mancini DM. Factors contributing to the exercise limitation of heart failure. J Am Coll Cardiol 1993; 22: 93A-8A.
-
(1993)
J am Coll Cardiol
, vol.22
, pp. 8A-93A
-
-
Wilson, J.R.1
Mancini, D.M.2
-
25
-
-
0037382775
-
Partial fatty acid oxidation (PFOX) inhibition: A new therapy for chronic stable angina
-
Conti CR. Partial fatty acid oxidation (pFOX) inhibition: a new therapy for chronic stable angina. Clin Cardiol 2003; 26: 161-162.
-
(2003)
Clin Cardiol
, vol.26
, pp. 161-162
-
-
Conti, C.R.1
-
26
-
-
0035917675
-
Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat
-
Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol 2001; 418: 105-110.
-
(2001)
Eur J Pharmacol
, vol.418
, pp. 105-110
-
-
Zacharowski, K.1
Blackburn, B.2
Thiemermann, C.3
-
27
-
-
33947431938
-
A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion
-
Wang P, Fraser H, Lloyd SG, McVeigh JJ, Belardinelli L, Chatham JC. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion. J Pharmacol Exp Ther 2007; 321: 213-220.
-
(2007)
J Pharmacol Exp Ther
, vol.321
, pp. 213-220
-
-
Wang, P.1
Fraser, H.2
Lloyd, S.G.3
McVeigh, J.J.4
Belardinelli, L.5
Chatham, J.C.6
-
28
-
-
0348129532
-
Combination Assessment of Ranolazine in Stable Angina (CARISA) Investigator. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial
-
Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA. Combination Assessment of Ranolazine in Stable Angina (CARISA) Investigator. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2007; 291: 309-316.
-
(2007)
JAMA
, vol.291
, pp. 309-316
-
-
Chaitman, B.R.1
Pepine, C.J.2
Parker, J.O.3
Skopal, J.4
Chumakova, G.5
Kuch, J.6
Wang, W.7
Skettino, S.L.8
Wolff, A.A.9
-
29
-
-
0035080560
-
Evidence that ranolazine behaves as a weak beta1-and beta2-adrenoceptor antagonist in the rat [correction of cat] cardiovascular system
-
Letienne R, Vie B, Puech A, Vieu S, Le Grand B, John GW. Evidence that ranolazine behaves as a weak beta1-and beta2-adrenoceptor antagonist in the rat [correction of cat] cardiovascular system. Naunyn Schmiedebergs Arch Pharmacol 2001; 363: 464-471.
-
(2001)
Naunyn Schmiedebergs Arch Pharmacol
, vol.363
, pp. 464-471
-
-
Letienne, R.1
Vie, B.2
Puech, A.3
Vieu, S.4
Le Grand, B.5
John, G.W.6
-
30
-
-
79958284578
-
Antiadrenergic and Hemodynamic Effects of Ranolazine in Conscious Dogs
-
Zhao G, Walsh E, Shryock JC, Messina E, Wu Y, Zeng D, Xu X, Ochoa M, Baker SP, Hintze TH, Belardinelli L. Antiadrenergic and Hemodynamic Effects of Ranolazine in Conscious Dogs. J Cardiovasc Pharmacol 2011; 57: 639-647.
-
(2011)
J Cardiovasc Pharmacol
, vol.57
, pp. 639-647
-
-
Zhao, G.1
Walsh, E.2
Shryock, J.C.3
Messina, E.4
Wu, Y.5
Zeng, D.6
Xu, X.7
Ochoa, M.8
Baker, S.P.9
Hintze, T.H.10
Belardinelli, L.11
-
31
-
-
84860443563
-
Effect of ranolazine on rat intrarenal arteries in vitro
-
Deng CY, Kuang SJ, Rao F, Yang H, Fang XH, Shan ZX, Li XH, Zhou ZL, Lin QX, Yang M, Wu SL, Yu XY, Lin SG. Effect of ranolazine on rat intrarenal arteries in vitro. Eur J Pharmacol 2012; 683: 211-216.
-
(2012)
Eur J Pharmacol
, vol.683
, pp. 211-216
-
-
Deng, C.Y.1
Kuang, S.J.2
Rao, F.3
Yang, H.4
Fang, X.H.5
Shan, Z.X.6
Li, X.H.7
Zhou, Z.L.8
Lin, Q.X.9
Yang, M.10
Wu, S.L.11
Yu, X.Y.12
Lin, S.G.13
|